Looking at the future sales market of Biopharmaceutics from the heavy bomb in the pharmaceutical Hall of fame

Source: from March 15, 2018 to the end of 2017, the cumulative sales of six prescription drugs exceeded US $100 billion The top three are Lipitor (Pfizer), sumerial (Albright) and erythropoietin (Amgen / Johnson) (table) According to the sales forecast, the sales volume of 100 billion drugs will reach 10 by 2022 It is worth noting that most of these promising drugs are biomacromolecule drugs High independent pricing power and long-term market exclusiveness make Biopharmaceutics have great advantages over small molecule drugs in drug sales market (especially in the United States) Recently, however, FDA director Scott Gottlieb said at the annual meeting of the U.S health insurance program that the current policy is not conducive to the development of biosimilars The United States lags behind Europe in terms of bio generics The reason is that large companies use patent barriers, marketing strategies and even delay the establishment of regulatory system to inhibit the development of bio generic drugs In the face of these problems, Gottlieb promised to promote the development of bio generic pharmaceutical market in terms of policies At the same time, he pointed out that there are many problems in the current market: drug kickbacks, alliance of drug interest management companies, insurance companies and innovative drug manufacturers, squeezing the profit space of bio generic pharmaceutical companies Pfizer sued J & J for using non competitive contracts to protect REMICADE's franchise The "kickback trap" is just one of the factors contributing to the high sales of biopharmaceuticals In addition, the good clinical efficacy of biological drugs and approved multiple indications are one of the reasons On the other hand, the technology of monoclonal antibody and recombinant protein is more complex than that of small molecule drugs, and the research and development is more difficult, which makes the price of biological drugs remain high If the current trend develops, by 2022, the top 10 drugs in terms of cumulative sales volume will be 7 biological drugs But these drugs face key decisions about sales in the next few years GlaxoSmithKline's patent for advair has expired, but the FDA has shelved its generic application Amgen is also trying to extend Enbrel's patent, and if it succeeds, the drug could continue to sell at a high volume for 10 years Alberto has spent a lot of manpower and material resources to extend the patent protection period of Humira for only a few months It turns out that abway's efforts are worth it Sumeria is expected to break the annual sales volume of $14 billion in the next five years, thus surpassing Lipitor to become the annual sales champion In addition, new base's Revlimid, Pfizer's prevnar 13 and immunotherapy anti-tumor drugs keytruda and opdivo have achieved great success in different fields It shows that biopharmaceutical has a great advantage in curative effect It is worth noting that FDA has realized the importance of limiting the "privilege" of biological drugs If the sales of drugs listed 20 years ago are still at the top of the list, it means that FDA should strengthen drug price control and promote generic drug market to promote competition.